Search Result

Results for "

epithelial ovarian cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Apoptosis (10) Arf Family GTPase (1) Aurora Kinase (1) Caspase (1) CD3 (1) CXCR (1) GABA Receptor (1) Glucosylceramide Synthase (GCS) (1) GnRH Receptor (4) Isotope-Labeled Compounds (3) Mitosis (1) Mucin (1)
By Research Areas:	Cancer (17) Endocrinology (5) Inflammation/Immunology (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-N2080

Songorine	GABA Receptor	Cancer
Songorine is a diterpenoid alkaloid isolated from the genus Aconitum. Songorine is a GABAA receptor antagonist in rat brain and has anti cancer, antiarrhythmic and anti-inflammatory activities. Songorine has the potential for the treatment of Epithelial ovarian cancer (EOC) .

HY-P99592

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific anti-CD3 and *anti-epithelial-cell-adhesion-molecule (EpCAM)* antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-116392B

DL-threo-PDMP hydrochloride	Glucosylceramide Synthase (GCS)	Cancer
DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P991608

CTM01 7F11C7	Mucin	Cancer
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .

HY-13673S2

Goserelin-d7 TFA	Isotope-Labeled Compounds Apoptosis GnRH Receptor	Endocrinology Cancer
Goserelin-d₇ (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673S

Goserelin-d10 ICI 118630-d₁₀	Isotope-Labeled Compounds	Endocrinology Cancer
Goserelin-d₁₀ (ICI 118630-d₁₀) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673S1

Goserelin-d7 ICI 118630-d₇	Isotope-Labeled Compounds GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin-d₇ (ICI 118630-d₇) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-157396

JAB-2485	Aurora Kinase Apoptosis Caspase	Cancer
JAB-2485 is an orally active and selective Aurora kinase A (AURKA) inhibitor with an IC₅₀ value of 0.327 nM. JAB-2485 exhibits inhibitory activity against various tumor cell lines such as neuroblastoma, triple-negative breast cancer, small cell lung cancer, and epithelial ovarian cancer. JAB-2485 can induce cell cycle arrest and apoptosis in tumor cells. JAB-2485 has antitumor activity .

HY-P99229

Upifitamab 1 Publications Verification	ADC Antibody	Cancer
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .

HY-134061

Arecaidine propargyl ester hydrobromide	Apoptosis Mitosis	Cancer
Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .

HY-173350

Ran-IN-1	Arf Family GTPase Apoptosis	Cancer
Ran-IN-1 (Compound M36) is an orally active and selective Ran GTPase inhibitor. Ran-IN-1 binds to the GDP-bound form of Ran (RanGDP) at the allosteric switch II pocket with high specificity, stabilizing the inactive state and reducing the active Ran-GTP population. Ran-IN-1 induces apoptosis and represses DNA repair pathways like HR and NHEJ in epithelial ovarian cancer (EOC) cells. Ran-IN-1 is promising for research of EOC, particularly high-grade serous carcinoma .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library	2,391 compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,391 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Anti-Ovarian Cancer Compound Library

2,391 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,391 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Cat. No.	Product Name	Target	Research Area